AR058406A1 - Antagonistas del receptor de proquineticina 1 - Google Patents

Antagonistas del receptor de proquineticina 1

Info

Publication number
AR058406A1
AR058406A1 ARP060105853A ARP060105853A AR058406A1 AR 058406 A1 AR058406 A1 AR 058406A1 AR P060105853 A ARP060105853 A AR P060105853A AR P060105853 A ARP060105853 A AR P060105853A AR 058406 A1 AR058406 A1 AR 058406A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
amino
pyridin
alkoxy
Prior art date
Application number
ARP060105853A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38158058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058406(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR058406A1 publication Critical patent/AR058406A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Antagonistas del receptor de proquineticina 1, y métodos para preparar estos compuestos, composiciones, intermediarios y derivados de los mismos y para el tratamiento de trastornos producidos por los receptores de proquineticina 1 o de proquinetina 1. Reivindicacion 1: Un compuesto de formula (1), donde, A1 es CF3, alcoxi C1-4, arilo, ariloxi, heterociclilo benzofusionado, o heteroarilo; donde arilo, ariloxi, y heteroarilo están opcionalmente sustituidos con pirazol-1-ilo [1,2,3]tiadiazol-4- ilo; o arilo, ariloxi, la porcion benzo del heterociclilo benzofusionado, y heteroarilo están opcionalmente sustituidos con uno a tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-6, hidroxialquilo C1-6, alcoxi C1- 6, halogeno, nitro, alquilo C1-6 halogenado, alcoxi C1-6 halogenado, alquiltio C1-6, alcoxi C1-6carbonilo, amino, alquil C1-6amino, di(alquil C1-6)amino, ciano, hidroxi, aminocarbonilo, alquil C1-6aminocarbonilo, di(alquil C1-6)aminocarbonilo, alcoxi C1-6carbonilamino, alquil C1-6carbonilo, alquiltio C1-6carbonilo, formilo, alquil C1-6sulfonilo, alquil C1-6sulfonilamino, aminosulfonilo, alquil C1-6aminosulfonilo, y di(alquil C1-6)aminosulfonilo; siempre y cuando A1 no sea 3,5-di-t-butil- fenilo; L1 es -(CH2)r-, -CH2-alquenil C2-4-, o -CH2CH2X(CH2)s-, donde L1 está opcionalmente sustituido con uno a dos sustituyentes independientemente seleccionados del grupo formado por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, y halogeno; y, r es un numero entero de 1 a 5; de tal modo que r es mayor que o igual a 4 cuando A1 es alcoxi C1-4; s es un numero entero de 1 a 3; X es O o S; D es -P-A2; donde P es -(CH2)1-2- o -CH2CH=CH- cuando A2 es fenilo, heterociclilo benzofusionado, heteroarilo, o cicloalquilo C3-8; alternativamente, P es -(CH2)3-6- cuando A2 es hidrogeno, alcoxi C1-4, o alcoxi C1-4carbonilo; y donde P está opcionalmente sustituido con uno a dos sustituyentes independientemente seleccionados del grupo formado por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, y halogeno; A2 es hidrogeno, alcoxi C1-4, alcoxi(C1-4)carbonilo, fenilo, heterociclilo benzofusionado, heteroarilo, tetrahidro-piranilo, piperidinilo, o cicloalquilo C3-8; donde fenilo, heteroarilo, la porcion benzo del heterociclilo benzofusionado, y cicloalquilo C3-8 están opcionalmente sustituidos con uno a tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-6, alcoxi C1-6, halogeno, alquilo C1-6 halogenado, alcoxi C1-6 halogenado, arilalcoxi C1-6, fenilo, N-isoindol-1,3-diona, alquiltio C1-6, alquil C1-6sulfonilo, alcoxi C1-6carbonilo, amino, alquil C1-6amino, di(alquil C1-6)amino, ciano, hidroxi, nitro, alquil C1-6carbonilo, alquiltio C1-6carbonilo, aminocarbonilo, alquil C1-6aminocarbonilo, di(alquil C1-6)aminocarbonilo, alquil C1-6carbonilamino, y un cicloalquiloxi C3-6 no fusionado; de tal modo que no más de dos sustituyentes en A2 son arilalcoxi C1-6, fenilo, N-isoindol-1,3-diona, o un cicloalquiloxi C3-6 no fusionado; siempre y cuando A2 no sea 3,5-di-t-butil-fenilo; W es N o C(Rw); donde Rw es H o alquilo C1-2; Q se selecciona del grupo formado por (a) a (g), donde (a) es -NH(CH2)Ar1 donde Ar1 es piridinilo opcionalmente sustituido con uno a tres sustituyentes alquilo C1-4 o un sustituyente seleccionado del grupo formado por alcoxi C1-4 y amino; siempre que cuando Ar1 es piridin-3-ilo no sustituido o piridin-4-ilo no sustituido, y A2 es 4-metoxi-fenilo, A1 no sea fenilo no sustituido o 3,4-dicloro-fenilo; (b) es -NHCH(Rz)-Ar2 donde Rz es H o alquilo C1-3; Ar2 es piridinilo, pirimidinilo, pirazinilo, la estructura de formula (2), 1,2,3,4-tetrahidro-[1,8]naftiridinilo, imidazo[1,2-a]piridinilo, o quinolinilo; de tal modo que el punto de union al 1,2,3,4-tetrahidro-[1,8]naftiridinilo está en la posicion 6 o 7, y el punto de union al quinolinilo está en la posicion 2, 3 o 4; y donde Ar2 está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-4, trifluorometilo, hidroxil-alquilo C1-4, aminoalquilo C1-4, (alquil C1-4)amino-alquilo C1-4, di(alquil C1-4)amino-alquilo C1-4, alcoxi C1-4, cicloalquil C3-8amino, amino, (alquil C1- 6)amino, y di(alquil C1-4)amino; o Ar2 está opcionalmente sustituido con un grupo amino y tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-4 y alcoxi C1-4, donde el grupo alquilo C1-6 de alquil C1-6amino y di(alquil C1-6)amino está opcionalmente sustituido con amino, alquil C1-4amino, di(alquil C1-4)amino, cicloalquil C3-8amino, alcoxi C1-4, alquiltio C1-4, hidroxi, un heteroarilo de 5 a 6 miembros, o un heterociclilo de 5 a 6 miembros; donde un átomo de nitrogeno del heterociclilo de 5 a 6 miembros está opcionalmente sustituido con un sustituyente alquilo C1-4; y donde piridin-2-ilo y piridin-3-ilo están además opcionalmente sustituidos con N-pirrolidinilo, N-piperazinilo, N-piperidinilo, N- morfolinilo, N-tiomorfolinilo, -CH2-O-CH2-PH, y fenilo; donde el sustituyente fenilo de piridin-2-ilo y piridin-3-ilo está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-4, alcoxi C1-4, y halogeno; siempre que cuando Q es -NHCH2(2-amino-piridin-3-il), y A1 es piridin-4-ilo, 4-alquil C1-6-fenilo, 3,4-dicloro-fenilo, o 4-metansulfonil-fenilo, A2 no sea 4-metoxi-fenilo; siempre que cuando Q es -NHCH2(2-amino-piridin-3- il), L1 es -(CH2)2- o .(CH2)5-, y A1 es metoxi, A2 no sea 4-difluorometoxi-fenilo o 4-metoxi-fenilo; siempre que cuando Q es -NHCH2(2-amino-piridin-3-il), y A1 es benzotriazol1-ilo, A2 no sea 4-difluorometoxi-fenilo; siempre que cuando Q es -NHCH2(2- amino-piridin-3-il), L1 es -(CH2)3-, y A1 es pirrol-1-ilo, A2 no sea 4-metoxi-fenilo; siempre que cuando Q es -NHCH2(2-amino-piridin-3-il), L1 es -(CH2)2-, y A1 es 4-nitro-fenilo o etoxi, A2 no sea 4-metoxi-fenilo; siempre que cuando Q es -NHCH2(2- amino-piridin-3-il), y A1 es 4-fluoro-fenilo, A2 no sea 4fluoro-fenilo; siempre que cuando Q es -NHCH2(6-amino-piridin-2-il), y A1 es 4-fluoro-fenilo, A2 no sea 4-trifluorometoxi-fenilo; siempre que cuando Q es .NHCH2(6-metil-piridin-2-il), y A1 es 4-metoxi-fenilo, A2 no sea 4-metoxi-fenilo; siempre que cuando Q es -NHCH2(imidazo[1,2-a]piridinil), y A1 es 4-fluoro-fenilo, A2 no sea 4-metoxi-fenilo; siempre que cuando Q es -NHCH2(piridin-4-il), y A1 es fenilo no sustituido o 3,4-dicloro-fenilo, A2 no sea 4-metoxi-fenilo; siempre que cuando Q es -NHCH2(4,6-dimetil-piridin-3-il), y A1 es 4-metoxi- fenilo, -P-A2 no sea -(CH2)5-metoxi; siempre que cuando Q es -NHCH2(4,6-dimetil-piridin-3-il), L1 es -(CH2)2-, y A1 es pirazol-1-ilo, A2 no sea 4- difluorometoxi-fenilo; siempre que cuando Q es -NHCH2(4,6-dimetil-piridin-3-il) y A1 es 4-metoxi-fenilo, A2 no sea 2-etil-fenilo, 4-etil-fenilo, 3-metoxi-fenilo, 3-ciano-fenilo, 3-nitro-fenilo, y 3-trifluorometil-4-nitro-fenilo; siempre que cuando Q es -NHCH2(4,6-dimetil-piridin-3-il) y A1 es quinolin-8-ilo, benzotriazol-1-ilo, 3,5-dimetil-pirazolilo, 2-fluoro-fenilo, 2-cloro-fenilo, 2-nitro-fenilo, 2-trifluorometil-fenilo, 2-difluorometoxi-fenilo, 3-difluorometoxi-fenilo, 2-trifluorometoxi- fenilo, 2,4-difluoro-fenilo, 2,6-difluoro-fenilo, 2,6-dicloro-fenilo, 2-cloro-4-fluoro-fenilo, 2,6-difluoro-4-metoxi-fenilo, o 4-trifluorometoxi-fenilo, A2 no sea 4-difluorometoxi-fenilo; y, siempre que cuando Q es -NHCH2(4,6-dimetil-piridin-3-il) y A1 es 3-nitro-4-metoxi-fenilo, 2,6-difluoro-4-metoxi-fenilo, o 3,4-dicloro-fenilo, A2 no sea 4-metoxi-fenilo; (c) es -CH2NHCH2-Ar3, donde W es N o CH, y Ar3 es piridinilo, pirimidinilo, 1,2,3,4-tetrahidro[1,8]naftiridinilo, imidazo[1,2-a]piridinilo, o quinolinilo; de tal modo que el punto de union al 1,2,3,4-tetrahidro-[1,8]naftiridinilo está en la posicion 6 o 7, y que el punto de union al quinolinilo está en la posicion 2, 3 o 4; donde Ar3 está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-4, aminoalquilo C1-4, (alquil C1-4amino-alquilo C1-4, di(alquil C1-4)amino-alquilo C1-4, alcoxi C1-4, amino, (alquil C1-6)amino, y di(alquil C1-6)amino; y donde el grupo alquilo C1-6 de (alquil C1-6)amino y di(alquil C1-6)amino está opcionalmente sustituido con amino, (alquil C1-4)amino, di(alquil C1-4)amino, cicloalquil C3-8amino, alcoxi C1-4, o hidroxi; (d) es -(CH2)2-Ar4, donde Ar4 es piridinilo, pirimidinilo, 1,2,3,4-tetrahidro-[1,8]naftiridinilo, imidazo[1,2-a]piridinilo, o quinolinilo; de tal modo que el punto de union a 1,2,3,4-tetrahidro-[1,8]naftiridinilo está en la posicion 6 o 7, y el punto de union al quinolinilo está en la posicion 2, 3 o 4; donde Ar4 está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-4, aminoalquilo C1-4, (alquil C1-4)amino-alquilo C1-4, di(alquil C1-4)amino-alquilo C1-4, alcoxi C1-4, amino, (alquil C1-6)amino, di(alquil C1-6)amino, halogeno, y aminocarbonilo; y donde el grupo alquilo C1-6 de (alquil C1-6)amino y di(alquil C1-6)amino está opcionalmente sustituido con amino, (alquil C1-4)amino, di(alquil C1-4)amino, cicloalquil C3- 8amino, alcoxi C1-4, o hidroxi; (e) es -CH=CH-Ar5 donde Ar5 es piridinilo, pirimidinilo, 1,2,3,4-tetrahidro-[1,8]naftiridinilo, imidazo[1,2-a]piridinilo, o quinolinilo; de tal modo que el punto de union al 1,2,3,4-tetrahidro-[1,8]naftiridinilo está en la posicion 6 o 7, y el punto de union al quinolinilo está en la posicion 2, 3 o 4; donde Ar5 está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados del grupo formado por alquilo C1-4, aminoalquilo C1-4, (alquil C1-4)amino-alquilo C1-4, di(alquil C1-4)amino-alquilo C1-4, alcoxi C1-4, amino, (alquil C1-6)amino, di(alquil C1-6)amino, halogeno, y aminocarbonilo; y donde el grupo alquilo C1-6 de (alquil C1-6)amino y di(alquil C1-6)amino está opcionalmente sustituido con amino, (alquil C1-4)amino, di(alquil C1-4)amino, cicloalquil C3-8amino, alcoxi C1-4, o hidroxi
ARP060105853A 2005-12-29 2006-12-28 Antagonistas del receptor de proquineticina 1 AR058406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75493905P 2005-12-29 2005-12-29

Publications (1)

Publication Number Publication Date
AR058406A1 true AR058406A1 (es) 2008-01-30

Family

ID=38158058

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105853A AR058406A1 (es) 2005-12-29 2006-12-28 Antagonistas del receptor de proquineticina 1

Country Status (10)

Country Link
US (2) US7902358B2 (es)
EP (2) EP1973886B1 (es)
JP (1) JP5452934B2 (es)
CN (2) CN101495464B (es)
AR (1) AR058406A1 (es)
CA (1) CA2635842C (es)
CL (1) CL2006003736A1 (es)
DK (1) DK1973886T3 (es)
IL (1) IL192424A0 (es)
WO (1) WO2007079163A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104715A1 (en) * 2005-03-24 2006-10-05 Janssen Pharmaceutica, N.V. Prokineticin 1 receptor antagonists
CN101495464B (zh) * 2005-12-29 2014-03-05 詹森药业有限公司 激肽原1受体拮抗剂
SG174016A1 (en) * 2006-07-24 2011-09-29 Korea Res Inst Chem Tech Hiv reverse transcriptase inhibitors
JP2011502154A (ja) * 2007-10-30 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。
MX2011008362A (es) 2009-02-13 2011-08-24 Shionogi & Co Derivado novedoso de triazina y composicion farmaceutica que comprende el mismo.
WO2012006004A1 (en) * 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
CA2807947C (en) 2010-08-10 2018-06-19 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
US9351972B2 (en) * 2010-11-29 2016-05-31 Galleon Pharmaceuticals, Inc. Compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201320905D0 (en) * 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
US9988373B2 (en) 2013-12-26 2018-06-05 Shionogi & Co., Ltd. Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same
EP3957627B1 (en) 2015-04-24 2024-06-19 Shionogi & Co., Ltd 6-membered heterocyclic derivative and pharmaceutical composition comprising same
WO2018074390A1 (ja) 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
CN110606827B (zh) * 2019-09-26 2023-03-14 西安凯立新材料股份有限公司 一步法合成甲氨基吡啶类化合物的方法
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205261A (ja) * 1985-03-08 1986-09-11 Sagami Chem Res Center ６―置換―５―フルオロウラシル誘導体
SE9704272D0 (sv) * 1997-11-21 1997-11-21 Astra Pharma Prod Novel Compounds
US6485938B1 (en) 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
EP1332157A2 (en) 2000-11-03 2003-08-06 The Regents of the University of California Prokineticin polypeptides, related compositions and methods
BR0313385A (pt) 2002-08-13 2005-06-14 Warner Lambert Co Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
WO2004014354A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2004032850A2 (en) 2002-10-07 2004-04-22 Zymogenetics, Inc. Uses of human zven antagonists
US7115560B2 (en) 2003-03-25 2006-10-03 The Regents Of The University Of California Methods for modulating gastric secretion using prokineticin receptor antagonists
CN102134229B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
AU2006229791A1 (en) 2005-03-24 2006-10-05 Janssen Pharmaceutica, N.V. Pyrimidindione derivatives as prokineticin 2 receptor antagonists
WO2006104715A1 (en) * 2005-03-24 2006-10-05 Janssen Pharmaceutica, N.V. Prokineticin 1 receptor antagonists
EP1868609A2 (en) * 2005-03-24 2007-12-26 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
CN101495464B (zh) * 2005-12-29 2014-03-05 詹森药业有限公司 激肽原1受体拮抗剂

Also Published As

Publication number Publication date
US20080269225A1 (en) 2008-10-30
IL192424A0 (en) 2009-02-11
DK1973886T3 (da) 2013-03-18
US20120028997A1 (en) 2012-02-02
CN101495464A (zh) 2009-07-29
EP2385042B1 (en) 2015-11-25
US7902358B2 (en) 2011-03-08
EP2385042A1 (en) 2011-11-09
JP2009522283A (ja) 2009-06-11
CA2635842C (en) 2015-02-17
WO2007079163A2 (en) 2007-07-12
CL2006003736A1 (es) 2008-05-16
EP1973886A2 (en) 2008-10-01
CN103396398A (zh) 2013-11-20
CN101495464B (zh) 2014-03-05
EP1973886B1 (en) 2013-02-27
WO2007079163A3 (en) 2007-08-30
CA2635842A1 (en) 2007-07-12
US8372973B2 (en) 2013-02-12
JP5452934B2 (ja) 2014-03-26

Similar Documents

Publication Publication Date Title
AR058406A1 (es) Antagonistas del receptor de proquineticina 1
AR058407A1 (es) Antagonistas del receptor de proquineticina 2
TN2018000295A1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EP1243582A4 (en) CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
DE60219672D1 (de) Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
WO2002051410A3 (en) Phenylthiazole and thiazoline derivatives and their use as antiparasitics
ATE294796T1 (de) Chinazolin derivate
DK0622361T3 (da) Heterocykliske forbindelser som bradykininantagonister
AR053700A1 (es) Antagonistas del receptor de proquineticina 2
DK7280A (da) Fremgangsmaade til fremstilling af (piperidinylalkyl) quinazolin-derivater
MX9804108A (es) Derivados de quinolina-4-carboxamida, su preparacion y uso como antagonistas receptores de neuroquinina 3 (nk-3)- y neuroquinina 2 (kn-2).
MX9700883A (es) Derivados sustituidos de la quinazolina.
MY118109A (en) Novel aralkyl amines of spirofuropyridines useful in therapy
AR047537A1 (es) Piridazinonaureas como antagonistas de integrinas
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
AR069127A1 (es) Antagonistas del receptor de procineticina 1 que contienen amino-heteroarilo
RS51550B (en) KAO DERIVATIVES KAO MODULATORS CCR5
AR053451A1 (es) Antagonistas del receptor de proquineticina 1
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
HRP20110344T1 (hr) Derivati dihidropiridina
AP9901695A0 (en) Quinoline-4-carbaoxamide derivatives as NK-2 and NK-3 receptor antagonists.
CA2371712A1 (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
ATE274518T1 (de) 6-(2-chlor-6-fluor-phenyl)-triazolpyrimidine
RU2149000C1 (ru) Применение карбоциклически и гетероциклически анеллированных дигидропиридинов и их фармацевтически приемлемых солей в качестве блокатора неселективных каналов катионов при защите головного мозга и лечении хронической бронхиальной астмы
BRPI0212215B8 (pt) compostos de ciclopenta[g]quinazolina anticâncer, uso dos mesmos para o tratamento de câncer e composição farmacêutica compreendendo dito composto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal